VCYT · Veracyte, Inc. · Insider Trading

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.38. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $43.50 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

Includes 361 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

Includes 514 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

Includes 389 shares of common stock purchased on July 31, 2026 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $49.89 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.30. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

The option is fully vested.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $48.80 to $49.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $49.88 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $48.84 to $49.84. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

Due to an administrative error, shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025 were incorrectly reported as 529 shares of common stock instead of 382 shares of common stock in a Form 4 filed on September 4, 2025, and these shares were overreported in subsequent Forms 4 filed by the Reporting Person. This column reflects the corrected balance.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.

The option is fully vested.

Represents weighted average sales price. Sale prices for the transactions range from $45.07 to $45.69. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025.

Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.

Restricted stock units awarded on April 10, 2026 vest 25% on June 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.